Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Diabetic Retinopathy or Retinal Vein Occlusion

Inclusion criteria

• ✓. Must have given written informed consent (signed and dated), and any authorizations required by local law and be able to comply with all study requirements
• ✓. Male or female, ≥18 years of age at the time of informed consent
• ✓. Females should have no childbearing potential according to Clinical Trial Facilitation Group (CTFG) definition.
• ✓. Clear ocular media and adequate pupillary dilation in the Study Eye to permit high quality retinal imaging
• ✓. Willing to refrain from unusually strenuous exercise/activity (for example heavy lifting, weight training, intense aerobics classes etc.) for at least 72 hours prior to study visits
• ✓. Diagnosed with moderately severe or severe non-proliferative Diabetic Retinopathy defined as having a DRSS score of 47 and 53 respectively, and no CI-DMO
• ✓. Found to have an ETDRS BCVA score in the study eye (SE) of ≥69 ETDRS (equivalent to Snellen 6/12 or 20/40)
• ✓. Diagnosed with Retinal Vein Occlusion with onset of symptoms within 28 days prior to first administration of ANXV

Exclusion criteria